Published in Mol Cancer Ther on November 09, 2010
Characterization of p38 MAPK isoforms for drug resistance study using systems biology approach. Bioinformatics (2014) 0.84
Dynamic balance of multiple myeloma clonogenic side population cell percentages controlled by environmental conditions. Int J Cancer (2014) 0.80
High throughput quantitative reverse transcription PCR assays revealing over-expression of cancer testis antigen genes in multiple myeloma stem cell-like side population cells. Br J Haematol (2014) 0.78
Discovering transcription and splicing networks in myelodysplastic syndromes. PLoS One (2013) 0.77
Rapid Anti-Inflammatory Effects of Gonadotropin-Releasing Hormone Antagonism in Rheumatoid Arthritis Patients with High Gonadotropin Levels in the AGRA Trial. PLoS One (2015) 0.75
Aptamer Internalization via Endocytosis Inducing S-Phase Arrest and Priming Maver-1 Lymphoma Cells for Cytarabine Chemotherapy. Theranostics (2017) 0.75
A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med (2003) 16.11
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med (2007) 8.41
A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood (2012) 5.11
Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med (2014) 5.08
Wnk1 kinase deficiency lowers blood pressure in mice: a gene-trap screen to identify potential targets for therapeutic intervention. Proc Natl Acad Sci U S A (2003) 4.70
Seroepidemiology of human polyomaviruses. PLoS Pathog (2009) 4.62
Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat Med (2006) 4.42
Fluid resuscitation in sepsis: a systematic review and network meta-analysis. Ann Intern Med (2014) 3.96
Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer. Blood (2007) 3.94
Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. Blood (2007) 3.67
Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins. J Clin Oncol (2013) 3.65
Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol (2006) 3.60
Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. Blood (2011) 3.58
Multigait soft robot. Proc Natl Acad Sci U S A (2011) 3.57
Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol (2004) 2.81
Proteasome inhibitors in multiple myeloma: 10 years later. Blood (2012) 2.77
Prognostic and predictive value of a microRNA signature in stage II colon cancer: a microRNA expression analysis. Lancet Oncol (2013) 2.67
High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol (2005) 2.62
Microsurgical keyhole approach for middle fossa arachnoid cyst fenestration. Neurosurgery (2003) 2.58
An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma. Blood (2012) 2.41
Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma. N Engl J Med (2015) 2.39
Targeting the p27 E3 ligase SCF(Skp2) results in p27- and Skp2-mediated cell-cycle arrest and activation of autophagy. Blood (2008) 2.36
LHRH antagonist Cetrorelix reduces prostate size and gene expression of proinflammatory cytokines and growth factors in a rat model of benign prostatic hyperplasia. Prostate (2010) 2.35
Dietary curcumin inhibits chemotherapy-induced apoptosis in models of human breast cancer. Cancer Res (2002) 2.33
Effect of vessel size on creation of hepatic radiofrequency lesions in pigs: assessment of the "heat sink" effect. AJR Am J Roentgenol (2002) 2.31
Shrinkage of experimental benign prostatic hyperplasia and reduction of prostatic cell volume by a gastrin-releasing peptide antagonist. Proc Natl Acad Sci U S A (2013) 2.19
A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies. Clin Cancer Res (2009) 2.17
New treatment approaches for prostate cancer based on peptide analogues. Eur Urol (2007) 2.13
The proteasome as a target for cancer therapy. Clin Cancer Res (2003) 2.13
American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. J Clin Oncol (2007) 2.09
Prospective phase II study of rituximab with alternating cycles of hyper-CVAD and high-dose methotrexate with cytarabine for young patients with high-risk diffuse large B-cell lymphoma. Br J Haematol (2013) 2.01
The proteasome and proteasome inhibitors in cancer therapy. Annu Rev Pharmacol Toxicol (2006) 1.99
Clinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120). Blood (2013) 1.98
Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma. Blood (2005) 1.95
An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib. Br J Haematol (2012) 1.94
Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma. Blood (2013) 1.89
Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004. Cancer (2008) 1.82
Constitutive association of the proapoptotic protein Bim with Bcl-2-related proteins on mitochondria in T cells. Proc Natl Acad Sci U S A (2004) 1.72
Life-cycle greenhouse gas emissions of shale gas, natural gas, coal, and petroleum. Environ Sci Technol (2011) 1.70
Antagonists of growth hormone-releasing hormone inhibit growth of androgen-independent prostate cancer through inactivation of ERK and Akt kinases. Proc Natl Acad Sci U S A (2012) 1.69
Plasmablastic lymphomas and plasmablastic plasma cell myelomas have nearly identical immunophenotypic profiles. Mod Pathol (2005) 1.66
Combination of an aptamer probe to CD4 and antibodies for multicolored cell phenotyping. Am J Clin Pathol (2010) 1.64
Combining growth hormone-releasing hormone antagonist with luteinizing hormone-releasing hormone antagonist greatly augments benign prostatic hyperplasia shrinkage. J Urol (2012) 1.62
Solitary plasmacytomas: outcome and prognostic factors after definitive radiation therapy. Cancer (2011) 1.61
Myeloma cell line-derived, pooled heat shock proteins as a universal vaccine for immunotherapy of multiple myeloma. Blood (2009) 1.61
Targeting beta2-microglobulin for induction of tumor apoptosis in human hematological malignancies. Cancer Cell (2006) 1.58
Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma. Blood (2012) 1.58
Macrophages are an abundant component of myeloma microenvironment and protect myeloma cells from chemotherapy drug-induced apoptosis. Blood (2009) 1.58
Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo. Am J Hematol (2009) 1.57
Evidence of a role for activation of Wnt/beta-catenin signaling in the resistance of plasma cells to lenalidomide. J Biol Chem (2010) 1.55
Detecting circulating tumor cells: current challenges and new trends. Theranostics (2013) 1.55
Wwp2, an E3 ubiquitin ligase that targets transcription factor Oct-4 for ubiquitination. J Biol Chem (2004) 1.53
Targeting MET kinase with the small-molecule inhibitor amuvatinib induces cytotoxicity in primary myeloma cells and cell lines. J Hematol Oncol (2013) 1.52
International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation. J Clin Oncol (2014) 1.52
Percutaneous mechanical and pharmacomechanical thrombolysis for occlusive deep vein thrombosis of the proximal limb in adolescent subjects: findings from an institution-based prospective inception cohort study of pediatric venous thromboembolism. J Vasc Interv Radiol (2011) 1.51
HIV-1 Tat targets microtubules to induce apoptosis, a process promoted by the pro-apoptotic Bcl-2 relative Bim. EMBO J (2002) 1.50
Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impared renal function. Cancer (2005) 1.50
Chromosome 8q24.1/c-MYC abnormality: a marker for high-risk myeloma. Leuk Lymphoma (2014) 1.48
An open-label single-arm pilot phase II study (PX-171-003-A0) of low-dose, single-agent carfilzomib in patients with relapsed and refractory multiple myeloma. Clin Lymphoma Myeloma Leuk (2012) 1.48
Novel selective inhibitors of nuclear export CRM1 antagonists for therapy in mantle cell lymphoma. Exp Hematol (2012) 1.47
Antagonists of growth hormone-releasing hormone inhibit the proliferation of human benign prostatic hyperplasia cells. Prostate (2010) 1.46
High-fat feeding-induced hyperinsulinemia increases cardiac glucose uptake and mitochondrial function despite peripheral insulin resistance. Endocrinology (2013) 1.46
Human C-reactive protein binds activating Fcgamma receptors and protects myeloma tumor cells from apoptosis. Cancer Cell (2007) 1.45
Phase II trial of neoadjuvant chemotherapy with docetaxel followed by epirubicin in stage II/III breast cancer. Breast Cancer Res Treat (2005) 1.45
Outcomes in lymphoma patients with obstructive jaundice: a cancer center experience. Dig Dis Sci (2010) 1.44
Double hit lymphoma: the MD Anderson Cancer Center clinical experience. Br J Haematol (2014) 1.43
Agonist of growth hormone-releasing hormone as a potential effector for survival and proliferation of pancreatic islets. Proc Natl Acad Sci U S A (2010) 1.42
Transforming the endocrine consult: asynchronous provider consultations. Endocr Pract (2015) 1.41
Neuroinflammation modulates distinct regional and temporal clinical responses in ALS mice. Brain Behav Immun (2010) 1.34
Mitogen-activated protein kinase phosphatase-1 is a mediator of breast cancer chemoresistance. Cancer Res (2007) 1.33
Adipose is a conserved dosage-sensitive antiobesity gene. Cell Metab (2007) 1.31
Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma. Biol Blood Marrow Transplant (2009) 1.31
An update on the use of degarelix in the treatment of advanced hormone-dependent prostate cancer. Onco Targets Ther (2013) 1.31
Cardioprotective effects of growth hormone-releasing hormone agonist after myocardial infarction. Proc Natl Acad Sci U S A (2010) 1.27
Dickkopf-1 (DKK1) is a widely expressed and potent tumor-associated antigen in multiple myeloma. Blood (2007) 1.26
Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myeloma. Clin Cancer Res (2007) 1.26
Using Internet search engines to obtain medical information: a comparative study. J Med Internet Res (2012) 1.25
Dysfunction of the TP53 tumor suppressor gene in lymphoid malignancies. Blood (2012) 1.25
RNase H active site inhibitors of human immunodeficiency virus type 1 reverse transcriptase: design, biochemical activity, and structural information. J Med Chem (2009) 1.24
Somatostatin receptor subtype 2 sensitizes human pancreatic cancer cells to death ligand-induced apoptosis. Proc Natl Acad Sci U S A (2002) 1.23
Antagonists of growth hormone-releasing hormone (GHRH) reduce prostate size in experimental benign prostatic hyperplasia. Proc Natl Acad Sci U S A (2011) 1.21
Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program Study. Haematologica (2012) 1.21
Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy. Blood (2013) 1.21
S-nitrosoglutathione reductase (GSNOR) enhances vasculogenesis by mesenchymal stem cells. Proc Natl Acad Sci U S A (2013) 1.20